Tecovirimat trial for monkeypox in DRC did not meet primary endpoint but showed improvements in early-onset, severe cases.

The PALM 007 trial of tecovirimat, an antiviral medication for monkeypox, did not meet its primary endpoint in a study in the Democratic Republic of Congo. However, the drug showed meaningful improvements in patients with early-onset symptoms and severe cases. The company's stock dropped by 38.3%. The safety profile of the treatment was comparable to placebo, and further clinical trials for tecovirimat are ongoing.